Drug interactions between Eldepryl and Sinemet CR
| Results for the following 2 drugs: |
|---|
| Eldepryl (selegiline) |
| Sinemet CR (carbidopa/levodopa) |
Interactions between your selected drugs
levodopa ↔ selegiline
Applies to:Sinemet CR (carbidopa/levodopa) and Eldepryl (selegiline)
ADJUST DOSE: When used as an adjunct to levodopa/carbidopa in the treatment of Parkinson's disease, selegiline may enhance levodopa-associated side effects in some patients. The presumed mechanism is enhanced peripheral catecholamine availability due to decreased degradation (MAOI activity) and increased synthesis (levodopa effect) of dopamine and, probably, norepinephrine. The concomitant administration of carbidopa has been reported to prevent or blunt the hypertensive response by inhibiting peripheral conversion of levodopa to dopamine.
MANAGEMENT: Two to three days after adding selegiline to the regimen, the levodopa/carbidopa dosage may require reduction by 10 to 30%. Due to the risks of nonselective MAO inhibition and drug interactions, selegiline doses should not exceed 10 mg/day.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
